Understanding and overcoming resistance in KRAS-driven cancers

Targeting Acquired Resistance in KRAS Driven Cancers

NIH-funded research University of Tx Md Anderson Can Ctr · NIH-10895586

This study is looking at why some cancers with a KRAS mutation don't respond to new treatments and aims to find better ways to help patients by understanding how these tumors resist therapy.

Quick facts

Grant typeR37 grant
Study typeNIH-funded research
Funding institutionUniversity of Tx Md Anderson Can Ctr NIH-funded
Lab location1 site (Houston, United States)
Project IDNIH-10895586 on NIH RePORTER

What this research studies

This research focuses on the challenges posed by treatment resistance in cancers driven by the KRAS mutation, which is common in various cancer types. The team will investigate how tumors develop resistance to newly approved KRAS inhibitors, using advanced laboratory models that mimic human cancer. By studying both cell cultures and patient-derived cancer models, the research aims to uncover the mechanisms behind this resistance and identify new treatment strategies that could improve patient outcomes.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients diagnosed with KRAS-driven cancers, such as pancreatic or colorectal cancer, who may benefit from targeted therapies.

Not a fit: Patients without KRAS mutations or those with cancers not driven by KRAS may not receive any benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective treatments for patients with KRAS-mutated cancers, potentially overcoming current limitations in therapy.

How similar studies have performed: Previous research has shown promise in targeting KRAS mutations, but this specific approach to understanding and overcoming resistance is novel and untested.

Where this research is happening

Houston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cancer GenesCancer ModelCancer TreatmentCancer cell lineCancer-Promoting Gene
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.